FrancophonIA/ELRC3.0 huggingface dataset:
English: Pegasys treatment should be discontinued in patients who develop new or worsening ophthalmologic disorders.
Croatian: Liječenje lijekom Pegasys treba prekinuti kod bolesnika koji za vrijeme liječenja razviju nove poremećaje ili kod kojih dođe do pogoršanja postojećih oftalmoloških poremećaja.
English: Pegasys is indicated for the treatment of hepatitis B envelope antigen (HBeAg)-positive or HBeAgnegative chronic hepatitis B (CHB) in adult patients with compensated liver disease and evidence of viral replication, increased alanine aminotransferase (ALT) and histologically verified liver inflammation and/or fibrosis (see sections 4.4 and 5.1).
Croatian: Pegasys je indiciran u liječenju kroničnog hepatitisa B pozitivnog na antigen ovojnice virusa hepatitisa B (HbeAg-pozitivnog) ili HBeAg-negativnog, u odraslih bolesnika s kompenziranom bolešću jetre i dokazom replikacije virusa, povišenom razinom alanin aminotransferaze (ALT) i histološki dokazanom upalom jetre i/ili fibrozom (vidjeti dijelove 4.4 i 5.1).
English: 1 Cochran-Mantel-Haenszel test, stratified by genotype (A vs. non-A) and baseline ALT (< 5 × ULN and >= 5 × ULN) 2 Fisher's Exact Test
Croatian: 1 Cochran-Mantel-Haenszelov test, stratificiran prema genotipu (A naspram ostalih) i početnoj vrijednosti ALT-a (< 5 × GGN i ≥ 5 × GGN)
English: The most frequently reported adverse reactions with Pegasys 180 micrograms were mostly mild to moderate in severity and were manageable without the need for modification of doses or discontinuation of therapy.
Croatian: Najčešće zabilježene nuspojave pri liječenju lijekom Pegasys u dozi od 180 mikrograma bile su uglavnom blagoga do umjerenog intenziteta bez potrebe za promjenom doze odnosno prekidom liječenja.
English: Psychiatric and nervous system disorders: Thoughts of suicide, hallucinations (severe problems with personality and deterioration in normal social functioning), peripheral neuropathy (disorder of the nerves affecting the extremities)
Croatian: Psihijatrijski poremećaji i poremećaji živčanog sustava: samoubilačke misli, halucinacije (teški problemi s osobnošću i pogoršanje normalnog funkcioniranja u društvu), periferna neuropatija (poremećaj živaca koji zahvaćaju udove)
English: A patient-level meta-analysis of 9 Pegasys clinical studies (n=1,423) in CHB HBeAg positive and HBeAg-negative patients demonstrated that HBsAg and HBV DNA levels at Week 12 of treatment, are predictive of final treatment outcome at Week 24 post-treatment in certain genotypes.
Croatian: Metaanaliza na razini bolesnika koja je obuhvatila 9 kliničkih ispitivanja lijeka Pegasys (n=1423) provedenih u HBeAg-pozitivnih i HBeAg-negativnih bolesnika s kroničnim hepatitisom B pokazala je da se na temelju razina HBsAg i HBV DNK u 12. tjednu liječenja kod određenih genotipova može predvidjeti konačan ishod liječenja u 24. tjednu nakon liječenja.
English: At the end of treatment, 43% of patients experienced a weight percentile decrease of 15 percentiles or more, and 25% (13 of 53) experienced a height percentile decrease of 15 percentiles or more on the normative growth curves.
Croatian: Na kraju liječenja je na normativnim krivuljama rasta u 43% bolesnika došlo do smanjenja percentila težine za 15 percentila ili više, a u njih 25% (13 od 53) do smanjenja percentila visine za 15 percentila ili više.
English: You should use a different place each time you give yourself an injection.
Croatian: Svaki put odaberite neko drugo mjesto za injekciju.
English: Dose-proportional increases in exposure of Pegasys are seen in healthy subjects and in patients with chronic hepatitis B or C after once-weekly dosing.
Croatian: Povećana, dozi proporcionalna izloženost lijeku Pegasys zamijećena je u zdravih ispitanika i bolesnika s kroničnim hepatitisom B ili C nakon primjene lijeka jedanput tjedno.
English: Store the container out of reach of children at all times.
Croatian: Spremnik uvijek čuvajte izvan dohvata djece.
English: For HBeAg-positive patients with HBV genotype B and C infection, HBsAg > 20,000 IU/mL or HBV DNA > 8 log10 IU/mL at Week 12 following commencement of treatment is associated with high likelihood of failure to achieve HBeAg seroconversion and HBV-DNA <2,000 IU/mL at 24 week post-treatment (NPV > 90%).
Croatian: U HBeAg-pozitivnih bolesnika s infekcijom HBV-om genotipa B i C, vrijednosti HBsAg > 20 000 IU/ml ili HBV DNK > 8 log10 IU/ml u 12. tjednu nakon početka liječenja povezane su s velikom vjerojatnošću nepostizanja HBeAg serokonverzije i vrijednosti HBV DNK < 2000 IU/ml u 24. tjednu nakon liječenja (NPV > 90%).
English: INFORMATION IN BRAILLE pegasys 135 mcg
Croatian: 16. PODACI NA BRAILLEOVOM PISMU pegasys 135 mcg
English: It is recommended that Pegasys pre-filled syringes be used for paediatric patients.
Croatian: Za pedijatrijske bolesnike preporučuje se koristiti Pegasys napunjene štrcaljke.
English: Caution should be exercised when administering Pegasys in combination with other potentially myelosuppressive agents.
Croatian: Potreban je oprez ukoliko se Pegasys primjenjuje s drugim potencijalno mijelosupresivnim lijekovima.
English: Patients receiving azathioprin in combination with ribavirin and peginterferon are at increased risk of developing severe blood disorders.
Croatian: Bolesnici koji uzimaju azatioprin u kombinaciji s ribavirinom i peginterferonom, imaju povećani rizik od pojave teških krvnih poremećaja.
English: Upper respiratory infection, bronchitis, fungal infection of the mouth and herpes (a common recurring viral infection affecting the lips, mouth) Blood disorders: Low platelet count (affecting the clotting ability), anaemia (low red cell count) and enlarged lymph glands
Croatian: Infekcija gornjeg dišnog sustava, bronhitis, gljivična infekcija usta i herpes (česta ponavljajuća virusna infekcija usana, usta) Poremećaji krvi: mali broj trombocita (utječe na sposobnost zgrušavanja krvi), anemija (niska razina crvenih krvnih stanica) i povećane limfne žlijezde.
English: For a few subjects who were more than 15 percentiles below their baseline height curve at 2 years post-treatment, they either returned to baseline comparable height percentiles at 6 years post-treatment or a non-treatment related causative factor has been identified.
Croatian: Šest godina nakon liječenja, nekolicina bolesnika, koji su 2 godine nakon liječenja bili više od 15 percentila ispod početne krivulje visine, se ili vratila na percentile visine usporedive s početnim vrijednostima ili je bio utvrđen uzročni faktor nepovezan s liječenjem.
English: *The active substance, peginterferon alfa-2a, is a covalent conjugate of the protein interferon alfa-2a produced by recombinant DNA technology in Escherichia coli with bis-[monomethoxy polyethylene glycol].
Croatian: * Djelatna tvar, peginterferon alfa-2a, kovalentni je spoj proteina interferona alfa-2a proizvedenog tehnologijom rekombinantne DNK u bakteriji Escherichia coli s bis[monometoksipolietilenglikolom].
English:  You might hear a second “click” as the activation button pops back up.
Croatian: → Kad se aktivacijsko dugme vrati u početni položaj možda ćete čuti i drugi „klik“.
English: Myalgia, arthralgia
Croatian: angina, aritmija,
English: Pegasys is presented as a solution for injection in a pre-filled syringe (0.5 ml) with a separate injection needle.
Croatian: Pegasys je dostupan u obliku otopine za injekciju u napunjenoj štrcaljki (0,5 ml) sa zasebnom iglom za injekciju.
English: Shortening the treatment duration in patients infected with genotype 2 or 3 with HVL (> 800,000 IU/ml) at baseline who become HCV negative by week 4 should be considered with more caution as this may significantly negatively impact the sustained virological response (see Table 1).
Croatian: Skraćivanje trajanja liječenja za bolesnike s genotipom 2 ili 3 i s HVL (> 800 000 IU/ml) na početku liječenja, koji su postali HCV negativni do 4. tjedna, treba razmotriti opreznije jer to može značajno negativno utjecati na trajni virološki odgovor (vidjeti tablicu 1).
English: Pegasys is designed for administration by the patient or carer.
Croatian: Pegasys je dizajniran tako da ga može primijeniti bolesnik ili njegovatelj.
English: You must use an effective contraceptive during the time you are taking the treatment and for 4 months after stopping treatment.
Croatian: Morate koristiti učinkovite mjere kontracepcije za vrijeme liječenja i 4 mjeseca nakon prestanka liječenja.
English: Genotype 2 or 3 RVR
Croatian: Genotip 2 ili 3 RVR
English: Patients co-infected with HIV and receiving Highly Active Anti-Retroviral Therapy (HAART) may be at increased risk of developing lactic acidosis.
Croatian: Bolesnici koji su uz HCV istodobno zaraženi i HIV-om te primaju viskoaktivnu antiretrovirusnu terapiju, tzv. HAART (od engl. highly active antiretroviral therapy) izloženi su povećanome riziku razvoja laktičke acidoze.
English: Exposure to Pegasys was decreased in studies following administration of Pegasys in the arm (see section 5.2).
Croatian: U ispitivanjima je izloženost lijeku Pegasys bila smanjena nakon primjene lijeka u nadlakticu (vidjeti dio 5.2).
English: In CHB or CHC patients, peginterferon alfa-2a serum concentrations accumulate 2 to 3 fold after 6 to 8 weeks of once weekly dosing compared to single dose values.
Croatian: Kod bolesnika s kroničnim hepatitisom B ili C koncentracije peginterferona alfa-2a akumuliraju se u serumu 2 do 3 puta više nakon 6 do 8 tjedana primjene jedanput tjedno, nego kod jednokratne primjene.
English: Treatment for only 16 weeks may be considered in selected patients infected with genotype 2 or 3 with LVL (≤ 800,000 IU/ml) at baseline who become HCV negative by week 4 of treatment and remains HCV negative by week 16.
Croatian: Liječenje u trajanju od samo 16 tjedana može se razmotriti za odabrane bolesnike zaražene genotipom 2 ili 3 s LVL (≤ 800 000 IU/ml) na početku liječenja, koji postanu HCV negativni do 4. tjedna liječenja i ostanu HCV negativni do 16. tjedna liječenja.
English: Anaemia (haemoglobin < 10 g/dl) was reported in 7% and 14% of patients treated with Pegasys monotherapy or in combination therapy, respectively.
Croatian: Anemija (hemoglobin < 10 g/dl) je zabilježena u 7% bolesnika koji su primali samo Pegasys odnosno u 14% bolesnika koji su primali kombinirano liječenje.
English: It is unknown whether peginterferon alfa-2a/metabolites are excreted in human milk.
Croatian: Nije poznato izlučuju li se peginterferon alfa-2a ili njegovi metaboliti u majčino mlijeko.
English: Treatment for 24 weeks may be considered in patients infected with - genotype 1 with low viral load (LVL) (≤ 800,000 IU/ml) at baseline or
Croatian: Liječenje u trajanju od 24 tjedna može se razmotriti za bolesnike zaražene - genotipom 1 s malom količinom virusa (LVL, engl. low viral load) (≤ 800 000 IU/ml) na početku liječenja ili - genotipom 4
English: Chronic hepatitis C
Croatian: Kronični hepatitis C
English: Genotype 2 or 3
Croatian: Genotip 2 ili 3
English: Decrease in ANC levels below 500 cells/mm3 was observed in 13% and 11% of patients receiving Pegasys monotherapy and combination therapy, respectively.
Croatian: Smanjenje razina ABN na manje od 500 stanica/mm primijećeno je u 13% bolesnika koji su primali samo Pegasys, odnosno u 11% bolesnika koji su primali kombinirano liječenje.
English: Regardless of the starting dose or degree of renal impairment, patients should be monitored and appropriate dose reductions of Pegasys during the course of therapy should be made in the event of adverse reactions.
Croatian: Bez obzira na početnu dozu odnosno stupanj oštećenja bubrega, ove bolesnike treba nadzirati te u slučaju nuspojava prikladno smanjivati dozu lijeka Pegasys.
English: Disposal of the injection materials
Croatian: Odlaganje materijala za ubrizgavanje
English: Do not:
Croatian: Nikako:
English: Genotype-A (N=9) Responder Genotype-B (N=21) Responder Genotype-C (N=34) Responder Genotype-D (N=31) Responder
Croatian: Svi genotipovi (N=101) Bolesnici s odgovorom Genotip A (N=9) Bolesnici s odgovorom Genotip B (N=21) Bolesnici s odgovorom Genotip C (N=34) Bolesnici s odgovorom Genotip D (N=31) Bolesnici s odgovorom
English: Injury, poisoning and procedural complications
Croatian: trovanja i proceduralne komplikacije predoziranje
English: The SVRs reported in the treatment arms of this study were similar to the corresponding treatment arms from study NV15942.
Croatian: Trajni virološki odgovor u liječenim grupama bio je sličan onome u odgovarajućim terapijskim grupama u ispitivanju NV15942.
English: (N=701) 48 weeks
Croatian: (N=701) 48 tjedana
English: The PK model developed from this study shows a linear influence of BSA on the apparent clearance of the drug over the age range studied.
Croatian: Farmakokinetički model razvijen na temelju ovog ispitivanja pokazuje linearni utjecaj tjelesne površine na prividni klirens lijeka u ispitivanom dobnom rasponu.
English: Patients with these conditions who cannot be effectively controlled by medication should not begin Pegasys monotherapy or Pegasys/ribavirin combination therapy.
Croatian: Bolesnici koji se nalaze u stanju koje nije moguće uspješno kontrolirati lijekovima, ne smiju započinjati monoterapiju lijekom Pegasys niti kombinirano liječenje lijekom Pegasys i ribavirinom.
English: In these patients, tolerability to combination therapy and additional prognostic factors such as degree of fibrosis should be taken into account when deciding on treatment duration.
Croatian: U takvih bolesnika, prilikom donošenja odluke o trajanju liječenja, treba uzeti u obzir kakva je podnošljivost kombiniranog liječenja, te dodatne prognostičke faktore kao što je stupanj fibroze.
English: Study YV25718 was conducted in previously untreated paediatric patients aged 3 to 17 years (51% < 12 years old) with HBeAg positive CHB and ALT > ULN but < 10 x ULN in two blood samples taken ≥ 14 days apart during the 6 months before the first dose of study drug.
Croatian: Ispitivanje YV25718 provedeno je u prethodno neliječenih pedijatrijskih bolesnika u dobi od 3 do 17 godina (51% bilo je mlađe od 12 godina) koji su imali HBeAg-pozitivan kronični hepatitis B i ALT > GGN-a, ali < 10 x GGN u dvama uzorcima krvi uzetima u razmaku od ≥ 14 dana unutar 6 mjeseci prije primjene prve doze ispitivanog lijeka.
English: The use of Pegasys and ribavirin combination therapy in CHC patients who failed prior treatment has not been adequately studied in patients who discontinued prior therapy for haematological adverse reactions.
Croatian: Primjena kombiniranog liječenja lijekom Pegasys i ribavirinom u bolesnika s kroničnim hepatitisom C koji nisu odgovorili na ranije liječenje nije dovoljno ispitana u bolesnika koji su prekinuli prethodno liječenje zbog hematoloških nuspojava.
English: Shortening the treatment duration in patients with genotype 1 and high viral load (HVL) (>800, 000 IU/ml) at baseline who become HCV RNA negative at week 4 and remain HCV RNA negative at week 24 should be considered with even more caution since the limited data available suggest that this may significantly negatively impact the sustained virologic response.
Croatian: Skraćivanje trajanja liječenja za bolesnike s genotipom 1 i velikom količinom virusa (HVL engl. high viral load) (> 800 000 IU/ml) na početku liječenja, a koji su u 4. tjednu postali HCV RNK negativni i ostali HCV RNK negativni i u 24. tjednu, treba razmotriti s još većom pažnjom jer ograničeni podaci koji su dostupni, upućuju da skraćivanje trajanja liječenja može značajno negativno utjecati na trajni virološki odgovor.
English: Chronic hepatitis C in prior non-responder patients
Croatian: Kronični hepatitis C u bolesnika koji nisu odgovorili na ranije liječenje
English: If the Pegasys dose is reduced or withheld, therapy can be restored once the flare is subsiding (see section 4.4).
Croatian: Ako se doza lijeka Pegasys smanji ili se lijek prestane uzimati, liječenje se može nastaviti nakon što se naglo porasle vrijednosti počnu smanjivati (vidjeti dio 4.4).
English: You or your partner must use an effective contraceptive during the time you are taking the treatment and for 7 months after stopping treatment.
Croatian: Vi ili Vaša partnerica morate koristiti učinkovite mjere kontracepcije za vrijeme liječenja i 7 mjeseci nakon prestanka liječenja.
English: Genotype 2-3
Croatian: Genotip 2-3
English: Ribavirin should be discontinued if either of the following applies: (1) a patient without significant cardiovascular disease experiences a fall in haemoglobin confirmed to < 8.5 g/dl; (2) a patient with stable cardiovascular disease maintains a haemoglobin value < 12 g/dl despite 4 weeks on a reduced dose.
Croatian: U bilo kojem od sljedeća dva slučaja, primjenu ribavirina treba prekinuti: (1) ako u bolesnika bez izražene bolesti kardiovaskularnog sustava hemoglobin padne ispod 8,5 g/dl; odnosno (2) ako bolesnik sa stabilnom bolesti kardiovaskularnog sustava i dalje ima razinu hemoglobina ispod 12 g/dl usprkos četverotjednom liječenju smanjenom dozom ribavirina.
English: Anti-interferon antibodies
Croatian: Antitijela na interferon
English: ● Take the short needle and place it firmly on to the tip of the syringe (5).
Croatian: Uzmite kratku iglu i čvrsto je postavite na vrh štrcaljke (5).
English: A subsequent study (NV18209) in patients co-infected with HCV genotype 1 and HIV compared treatment using Pegasys 180 mcg/week and either ribavirin 800 mg or 1000 mg (<75 kg)/1200 mg (≥75 kg) daily for 48 weeks.
Croatian: Dodatno ispitivanje (NV 18209) u bolesnika istodobno zaraženih HCV-om genotipa 1 i HIV-om uspoređivalo je liječenje lijekom Pegasys 180 mikrograma/tjedan u kombinaciji s ribavirinom 800 mg ili 1000 mg (< 75 kg)/1200 mg (≥ 75 kg) dnevno kroz 48 tjedana.
English: Overall, the safety profile for Pegasys in combination with ribavirin in prior non-responder patients was similar to that in naïve patients.
Croatian: Općenito, sigurnosni profil primjene lijeka Pegasys u kombinaciji s ribavirinom u bolesnika koji nisu odgovorili na ranije liječenje, bio je sličan onome u bolesnika koji još nikada nisu bili liječeni.
English: In addition, dry mouth could have a damaging effect on teeth and mucous membranes of the mouth during long-term treatment with the combination of Pegasys and ribavirin.
Croatian: Uz to suhoća usta može imati štetne posljedice na zube i sluznicu usta tijekom dugotrajnog liječenja kombinacijom lijeka Pegasys i ribavirina.
English: If you realise you missed your injection 3 to 5 days after it was scheduled, you should take your injection at the recommended dose as soon as possible.
Croatian: Ako je prošlo 3 do 5 dana od vremena kada ste trebali primiti dozu lijeka, trebate primiti preporučenu dozu što je moguće prije.
English: Chronic Hepatitis C: Pegasys is used in combination with other medicines, for the treatment of chronic hepatitis C (CHC).
Croatian: Kronični hepatitis C: Pegasys se za liječenje kroničnog hepatitisa C koristi u kombinaciji s drugim lijekovima.
English: 0.5 ml of solution for injection in pre-filled syringe (siliconised Type I glass) with a plunger stopper and tip cap (butyl rubber laminated on the product facing side with fluororesin) with a needle.
Croatian: 0,5 ml otopine za injekciju u napunjenoj štrcaljki (silikonzirano staklo tipa I), s čepom klipa i zatvaračem vrha (butilna guma obložena fluorosmolom na strani koja je u dodiru s lijekom) s iglom.
English: Duration of treatment - dual therapy with Pegasys and ribavirin The duration of combination therapy with ribavirin for CHC depends on viral genotype.
Croatian: Trajanje liječenja - dvojna terapija lijekom Pegasys i ribavirinom Trajanje kombiniranoga liječenja kroničnoga hepatitisa C lijekom Pegasys i ribavirinom ovisi o genotipu virusa.
English: solution for injection
Croatian: otopina za injekciju
English: ● If you have any further questions, ask your doctor, pharmacist or nurse.
Croatian: • Ako imate dodatnih pitanja, obratite se liječniku, ljekarniku ili medicinskoj sestri.
English: For HBeAg-negative patients with HBV genotype D infection, HBsAg > 20,000 IU/mL or HBV DNA > 6.5 log10 IU/mL at Week 12 following commencement of treatment is associated with high likelihood of failure to achieve HBV-DNA <2,000 IU/mL and ALT normalization at Week 24 post treatment.
Croatian: U HBeAg-negativnih bolesnika s infekcijom HBV-om genotipa D, vrijednosti HBsAg > 20 000 IU/ml ili HBV DNK > 6,5 log10 IU/ml u 12. tjednu nakon početka liječenja povezane su s velikom vjerojatnošću nepostizanja vrijednosti HBV DNK < 2000 IU/ml i normalizacije ALT-a u 24. tjednu nakon liječenja.
English: Table 22: Serological, virological and biochemical responses in paediatric patients with chronic hepatitis B
Croatian: Tablica 22: Serološki, virološki i biokemijski odgovori u pedijatrijskih bolesnika s kroničnim hepatitisom B
English: In study NR16071, HCV patients with normal ALT values were randomised to receive Pegasys 180 micrograms/week and ribavirin 800 milligrams/day for either 24 or 48 weeks followed by a 24 week treatment free follow-up period or no treatment for 72 weeks.
Croatian: U ispitivanju NR16071, HCV bolesnici s normalnim razinama ALT-a randomizirani su za primanje 180 mikrograma lijeka Pegasys tjedno i 800 miligrama ribavirina dnevno tijekom 24 odnosno 48 tjedana nakon čega je slijedio period praćenja bez liječenja 24 tjedna ili su praćeni bez liječenja u trajanju od 72 tjedna.
English: Genotype 1 or 4 without RVR*
Croatian: Genotip 1 ili 4 bez RVR*
English: In clinical trials of 48 weeks treatment and 24 weeks follow-up, the safety profile for Pegasys in CHB was similar to that seen in CHC.
Croatian: U kliničkim ispitivanjima liječenja u trajanju od 48 tjedana i praćenja tijekom sljedeća 24 tjedna pokazalo se da je sigurnosni profil lijeka Pegasys kod kroničnog hepatitisa B sličan profilu zabilježenom kod kroničnog hepatitisa C.
English: Adjustments in the recommended dosage of 180 micrograms once weekly are not necessary when instituting Pegasys therapy in elderly patients (see section 5.2).
Croatian: U starijih bolesnika prilikom liječenja lijekom Pegasys nije potrebno prilagođavati preporučenu dozu od 180 mikrograma na tjedan (vidjeti dio 5.2).
English: Male patients or their female partners must use an effective contraceptive during treatment and for 7 months after treatment has been concluded.
Croatian: Bolesnici ili njihove partnerice moraju koristiti učinkovite mjere kontracepcije za vrijeme liječenja i 7 mjeseca nakon prestanka liječenja.
English: For persistent ALT values ≥10 x ULN discontinue treatment.
Croatian: Kod trajno povišenih vrijednosti ALT-a ≥ 10 x iznad GGN, obustaviti liječenje.
English: Change your injection site each time.
Croatian: Svaki put odaberite drugo mjesto za injekciju.
English: If you realise you missed your injection 1 or 2 days after it was scheduled, you should inject your recommended dose as soon as possible.
Croatian: Ako je prošao 1 ili 2 dana od vremena kada ste trebali primiti dozu lijeka,trebate primiti preporučenu dozu što je moguće prije.
English: HIV-HCV co-infection
Croatian: Bolesnici s HIV-HCV koinfekcijom
English: Combination therapy with ribavirin in chronic hepatitis C In the case of combination therapy with Pegasys and ribavirin, please follow the dosing regimen recommended by your doctor.
Croatian: Kombinirana terapija s ribavirinom u liječenju kroničnog hepatitisa C Ako Vam je propisano liječenje lijekom Pegasys u kombinaciji s ribavirinom, molimo pridržavajte se načina doziranja koji Vam je propisao liječnik.
English: Digestive system disorders: Vomiting, indigestion, difficulty swallowing, mouth ulceration, bleeding gums, inflammation of tongue and mouth, flatulence (excess amount of air or gases), dry mouth and loss of weight
Croatian: Poremećaji probavnog sustava: povraćanje, probavne tegobe, otežano gutanje, vrijed usta, krvarenje iz desni, upala jezika i usta, nadutost (povećana količina zraka ili plinova), suha usta i gubitak težine